Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Concentrate safety and efficacy.

C K Kasper1

  • 1Orthopaedic Hospital, 2400 South Flower Street, Los Angeles, CA 90007, USA. ckasper@laoh.ucla.edu

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 16, 2002
PubMed
Summary

Plasma-derived clotting factor concentrates are safe due to advanced screening and viral inactivation. However, potency assay discrepancies require further investigation for optimal therapeutic use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An elective orthopaedic surgical repair: a reminiscence.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

In vivo recovery and early half-life of infused factor VIII in haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Judith Graham Pool and the discovery of cryoprecipitate.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Preimplantation genetic diagnosis--a historical annotation: first PGD baby turns fifteen.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Haemophilia management: time to get personal?

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

How many carriers are there?

Haemophilia : the official journal of the World Federation of Hemophilia·2010

Area of Science:

  • Hematology
  • Virology
  • Biotechnology

Background:

  • Ensuring safety of plasma-derived clotting factor concentrates is critical.
  • Infection transmission risks have been mitigated through enhanced screening and viral inactivation.

Purpose of the Study:

  • To review the safety measures for plasma-derived clotting factor concentrates.
  • To discuss advancements in viral inactivation techniques.
  • To address discrepancies in concentrate potency assays.

Main Methods:

  • Review of donor screening protocols.
  • Analysis of serological and viral testing methods.
  • Evaluation of modern viral inactivation techniques.
  • Assessment of in vitro versus in vivo potency assay discrepancies.

Main Results:

  • Improved donor screening and viral testing ensure safety.
  • Modern viral inactivation methods are highly effective.
  • Recombinant concentrates are transitioning to new stabilizers.
  • Discrepancies in potency estimates between in vitro and in vivo assays persist.

Conclusions:

  • Plasma-derived clotting factor concentrates are safe for patient use.
  • Ongoing research is needed to resolve potency assay discrepancies.
  • Advancements in manufacturing and testing continue to improve product safety and efficacy.

Related Experiment Videos